As a primary driver of cardiovascular morbidity and mortality, perioperative tachycardia represents a significant clinical challenge that requires careful management. The physiological stress of surgical intervention triggers a surge in catecholamine concentrations, which can increase heart rate, blood pressure, and free fatty acid levels. This sympathomimetic response escalates myocardial oxygen demand while simultaneously reducing the duration of diastole, the critical period during which the left ventricle receives its perfusion, potentially leading to myocardial injury. Effective management requires heart rate control and the attenuation of the sympathetic stress response.
Historically, beta-adrenoceptor blocking agents (beta blockers) such as metoprolol, esmolol, and landiolol have been the cornerstone of the management of perioperative tachycardia due to their ability to block the actions of epinephrine and norepinephrine. However, large-scale trials like POISE demonstrated that while high-dose, extended-release metoprolol succinate could reduce the incidence of myocardial infarction, it significantly increased the risks of stroke and overall mortality. The suspected mechanism of this harmful complication is drug-induced hypotension and bradycardia, which can compromise organ perfusion.
Current evidence-based practice has moved away from reflexive prophylactic beta-blockade in stable patients, instead reserving these agents for the targeted management of patients who are actively tachycardic and hypertensive. Short-acting, selective beta-1 antagonists like esmolol are particularly advantageous in the perioperative setting for the acute management of supraventricular tachyarrhythmias because their effects can be rapidly titrated or discontinued.
Beyond beta-blockers, alternative pharmacological strategies focusing on sympathetic attenuation have gained prominence. Dexmedetomidine, an alpha-2 adrenergic agonist, has been shown to lower heart rates and stabilize the hemodynamic profile more effectively than traditional sedatives like midazolam. Furthermore, intravenous lidocaine can be utilized to block sympathetic-mediated tachycardia and hypertension while attenuating the overall stress response to surgical stimulation. The choice of anesthetic technique also plays a vital role; for instance, the use of neuraxial blocks or minimally invasive surgical approaches can significantly lower the rate of perioperative arrhythmias and myocardial injury by reducing the intensity of the sympathetic surge.
When dealing with specific tachyarrhythmias such as supraventricular tachycardia (SVT), the clinician must distinguish between different underlying mechanisms in order to focus management on the root cause. Adenosine remains both a diagnostic and therapeutic tool; it can terminate re-entry tachycardias involving the atrioventricular (AV) node but provides only transient ventricular rate slowing in cases of atrial fibrillation or flutter. Postoperative atrial fibrillation occurs in approximately 3% of the surgical population, necessitating diligent rate control to prevent hemodynamic instability.
Ultimately, the management of perioperative tachycardia should focus on preserving adequate diastolic perfusion time and avoiding the hemodynamic extremes of hypotension. Clinicians must balance the necessity of heart rate reduction with the potential risks of aggressive pharmacological intervention, ensuring that therapy is tailored to the patient’s specific hemodynamic requirements and the surgical context.
References
- Blessberger, H. et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing non-cardiac surgery. Cochrane Database of Systematic Reviews 9, CD013438 (2019). https://doi.org/10.1002/14651858.CD013438
- Thompson, A. & Balser, J. R. Perioperative cardiac arrhythmias. British Journal of Anaesthesia 93, 86–94 (2004). https://doi.org/10.1093/bja/aeh166
- POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. The Lancet 371, 1839–1847 (2008). https://doi.org/10.1016/S0140-6736(08)60601-7
- Zeppenfeld, K. et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal 43, 3997–4126 (2022). https://doi.org/10.1093/eurheartj/ehac262
- Bohringer, C., Le, D. & Liu, H. Current Concepts in the Prevention of Perioperative Myocardial Injury. Translational Perioperative and Pain Medicine 7, 279–287 (2020). https://doi.org/10.31480/2330-4871/127